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  Total hip arthroplasty (THA) registers are established in 
several countries to collect data aiming to improve the 
results after THA. Monitoring of adverse outcomes after 
THA has focused mainly on revision surgery, but patient-
reported outcomes have also been investigated.
  Several surgery-related factors influencing the survival 
of the THA have been thoroughly investigated and have 
changed clinical practice. These factors include surgical 
approach, specific implants, the size of the components, 
type of fixation and different bone cements.
  Register data have been used to examine the risk of venous 
thromboembolism and bleeding after THA. These investi-
gations have resulted in shorter duration of thrombopro-
phylaxis and a reduced frequency of blood transfusion.
  Registers may provide specific information to surgeons on 
the outcome of all THAs that they have performed with 
a detailed analysis of revisions rates and reasons for the 
revisions.
  A number of other stakeholders can use register data to 
provide benchmarks. The National Joint Registry for Eng-
land, Wales, Northern Ireland and the Isle of Man supplies 
data to the Orthopaedic Device Evaluation Panel (ODEP), 
which provides benchmarks at 3, 5, 7, 10, and 13 years 
graded from A*, A, B and C.
  Future perspectives: National registers have to play a 
major role in documenting the quality of THA in order 
to describe best practice and report implant outliers. The 
registers have to be used for research and post-market sur-
veillance and register data may be a source for intelligent 
decision tools.
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Background
The establishment of total hip arthroplasty (THA) registers 
started in the Scandinavian countries in 1979.1 Later on, 
several countries outside Scandinavia followed with the 
establishment of nationwide or regional THA registers. The 
aim of the registers was to collect patient- and surgery-
related data to influence surgeons’ choice of implants, fix-
ation method, patient selection and peri-operative 
management and to improve the outcome after THA. This 
impact of the registers on orthopaedic practice can be 
obtained by open access transparent publication of results 
in scientific journals and annual reports, discussion of 
results and the role of registers at meeting in the ortho-
paedic community, feedback mechanisms to the hospitals 
and regulatory bodies and so on. The impact of registers 
may be evaluated by measuring the influence on mortal-
ity, quality of care including patient safety (complications) 
and effectiveness (adherence to clinical guidelines), 
healthcare utilization and healthcare costs.2
Each register contains data that make it possible to inves-
tigate rare events; this may be even more obvious with col-
laboration of registers.3,4 Data from hip arthroplasty registers 
Impact of hip arthroplasty registers on orthopaedic 













 General Orthopaedics  
369
Impact of hIp arthroplasty regIsters
have mainly been used to investigate adverse outcomes of 
primary THA leading to revision surgery.5-7 In some coun-
tries, a unique personal identification number makes it pos-
sible to combine healthcare data at a personal level and 
investigate adverse outcomes other than those related to 
surgery, e.g. medical outcomes and mortality.8,9
To our knowledge, only Malchau et al have reported 
on the development and impact of arthroplasty implant 
registers based on two American and two Swedish regis-
ters.10 The focus of this paper is to report examples of 
some of the European and the Australian THA quality reg-
isters that had had an impact on clinical practice and to 
give future perspectives of the registers’ role.
Examples of impact
The Swedish Hip Arthroplasty Register
Established in 1979, the Swedish Hip Arthroplasty Register 
(SHAR) was the world’s first national quality register col-
lecting data on hip arthroplasty.1 A few years after its 
inception, all hospitals performing hip arthroplasty in 
Sweden contributed and have continued to do so. Ortho-
paedic surgeons soon learnt to appreciate the feedback of 
results. The first large long-term follow-up study based on 
the register highlighted the importance of implant selec-
tion and cementing technique.11 Several underperform-
ing implants associated with worse implant survival were 
identified resulting in change of practice. This study was 
among the first to demonstrate the importance of system-
atic implant surveillance through an arthroplasty register. 
For example, owing to Swedish surgeons’ cautious atti-
tude towards undocumented new concepts, Sweden 
avoided the catastrophes associated with metal-on-metal 
(MoM) implants. Today, six different stem designs account 
for > 92% of all femoral components used in THA in Swe-
den. Likewise, for acetabular components, ten different 
cup designs account for > 82% of the production.12
Thein et al investigated design-related features of the 
three most commonly used stems in Sweden. Although 
the most common stem had the lowest crude revision 
rate, the smallest stem size and extended femoral head 
were associated with increased risk of revision.13 After pre-
senting the findings, there was a marked decrease in the 
use of components with these particular attributes.
The inclusion of hemiarthroplasties in the Swedish Hip 
Arthroplasty Register in 2005 was yet another pioneering 
work. Very few national arthroplasty registers comprise 
hemiarthroplasties. Due to the established data collection 
routines, all hospital units immediately joined with a com-
pleteness at case level of 95%.12 Early findings on surgical 
approaches and the risk of dislocation dramatically influ-
enced the choice of surgical technique in favour of the 
direct lateral approach.14,15 Doubtless, Swedish register 
data support the exceptionally high use of cemented fixa-
tion in hemiarthroplasties: uncemented stems carry an 
increased risk of re-operation in general and due to peri-
prosthetic fracture, in particular, without differences in 
mortality.15 Subsequently, Sweden has withstood the 
increasing use of uncemented fixation for hemiarthro-
plasty observed internationally.
In 2002, a prospective patient-reported outcome meas-
ures (PROMs) follow-up programme was introduced in 
the SHAR and became nationwide in 2008. Patients are 
asked to complete the PROMs, including the EQ-5D-3L 
and EQ VAS, pre-operatively and at different time-points 
after THA surgery. Since the introduction, a small improve-
ment in the PROMs has been demonstrated.16,17 Hence, 
the impact of the SHAR on arthroplasty practice in Sweden 
is not attributable to isolated major discoveries. It is based 
on continuous in-depth analyses, persistent communica-
tion with the profession and open reporting of results at 
hospital unit level. The resulting homogeneous use of 
well-documented implants and methods has yielded out-
standing long-term implant survivorship.18
The Finnish Arthroplasty Register
The Finnish Arthroplasty Register (FAR) was founded in 
1980. Based on FAR data, Puolakka et al reported a nine-
year survival rate of only 65% (95% confidence interval 
(CI) 61 to 69) for the cementless Biomet THA which was 
due to the inferiority of the cup and the hexaloc locking 
mechanism of polyethylene liner. The authors recom-
mended that Biomet cups with hexaloc liners should be 
abandoned.19
In 2005, Eskelinen et al evaluated the population-based 
survival of THA fixation methods in osteoarthritis patients 
aged < 55 years and the factors affecting survival. It was 
shown that, for younger patients, uncemented proximally 
circumferentially porous- and hydroxyapatite-coated 
stems are the implants of choice.20 The results for patients 
aged < 55 years with rheumatoid arthritis were similar.21 
These publications notably supported that uncemented 
THA became very popular in Finland.
The Norwegian Arthroplasty Register
The Norwegian Arthroplasty Register started as a hip reg-
ister in 1987; from the start, it followed patients from pri-
mary operation to revision of the implant or death using 
the unique 11-digit person identification of Norwegian 
inhabitants. The unique catalogue number of implants 
was entered into an implant library using the implant 
stickers, thus enabling the register to document poor-per-
forming implants from an early stage. After five years of 
service, the register identified that cemented hip implants 
had better short-term results, both in young and older 
patients, than uncemented implants.22-24 This was mainly 
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due to poor fixation of uncemented cups without rough-
ened surface and stems without circumferential rough-
ened surfaces. With longer follow-up to ten years, the 
uncemented cups with initial good performance per-
formed poorly due to wear of the polyethylene liner.25,26 
Several bone cements were also identified as poorly per-
forming after only three years of follow-up, especially the 
Boneloc cement and a low viscosity cement.27,28 With a 
longer follow-up, three cemented implants—the Titan 
stem, the Spectron EF stem and the non-crosslinked EtO 
sterilized all-polyethylene Reflection cup—had inferior 
performance.29,30 Some uncemented hemispherical cups 
and fully coated uncemented stems had good long-term 
fixation.31,32 The surgeons instantly stopped using the 
implants if a specific implant was identified as poorly per-
forming and, in the Nordic countries, the use of cement 
containing antibiotics was established as routine after 
publications of fewer revisions due to infections.33,34
Documentation of poorly performing implants, cements 
and techniques have led to lower revision rates, reduced 
healthcare cost and reduced suffering for patients.35-37
The Danish Hip Arthroplasty Register
The Danish Hip Arthroplasty Register (DHR) was established 
in 1995.38,39 Besides important monitoring in annual reports 
and specific studies on patient- and implant-related risk fac-
tors for adverse outcome,40-42 other adverse outcomes 
including venous thromboembolism (VTE) and blood trans-
fusion have also been thoroughly investigated.
Pharmacological thromboprophylaxis is a standard and 
well-accepted peri-operative treatment. Despite treat-
ment, risk of symptomatic VTE has been reported to be up 
to 6% within 90 days of THA surgery.43-45 In Denmark, the 
risk of symptomatic VTE within 90 days is 1%46 and has 
been stable during the last 15 years despite change in 
prophylaxis practice. The duration of the treatment has 
been a matter of debate for years and there is no consen-
sus in guidelines regarding duration of thromboprophy-
laxis. The 2012 American College of Chest Physicians 
guidelines recommended using anticoagulation drugs for 
a minimum of 10 to 14 days with grade 1B evidence and 
suggested extending prophylaxis for up to 35 days with 
grade 2B evidence.47 The 2012 guidelines from the 
National Institute for Health and Care Excellence recom-
mended prophylaxis for 28 to 35 days.48 In contrast, the 
2011 guidelines from the American Academy of Orthope-
dic Surgeons recommended individual assessment of the 
optimal duration of thromboprophylaxis without any 
elaboration on the THA patients who may benefit from 
extended prophylaxis.49 Administration of extended 
thromboprophylaxis after THA has proven difficult in 
many clinical settings; concerns about treatment benefit 
and risk in routine clinical practice have remained. In 
2015, a study was published based on data from the DHR, 
examining risk of symptomatic VTE and major bleeding 
associated with short-term (1 to 6 days), medium-term (7 
to 27 days) compared with extended (⩾ 28 days) therapy. 
The 90-day risks of VTE were 1.1% (short), 1.4% (medium) 
and 1.0% (extended), yielding an adjusted hazard ratio of 
0.83 (95% CI 0.52 to 1.31) and 0.82 (95% CI 0.50 to 1.33) 
for short and standard versus extended treatment. Risk of 
bleeding was similar in the three groups.50 This study was 
the key piece of evidence for making national Danish 
guidelines regarding thromboprophylaxis: 1) thrombo-
prophylaxis for THA patients should not exceed ten days; 
and 2) prophylaxis for THA performed in fast-track set-
tings should not exceed length of stay when hospitalized 
for a maximum of five days.51
In 2009, a study based on DHR data reported on sub-
stantial differences in the use of red blood cell transfusion 
among THA patients in Danish orthopaedic departments 
(16% to 64%). The differences in the use of blood transfu-
sions could not be explained by a range of patient- and 
surgery-related factors, which suggested that the variation 
did not reflect differences in the patients' need for blood 
transfusion, but rather true differences in transfusion pol-
icy.52 In addition, the same group published that red 
blood cell transfusion was associated with an adverse 
prognosis following primary THA, in particular with 
increased odds of death and pneumonia.53 Subsequently, 
a new quality indicator was initiated in the DHR: ‘Use of 
blood transfusion within 7 days of THA surgery’ linking 
DHR with data from the Danish Transfusion Database. 
During the period 2010 to 2016, the average use of blood 
transfusion decreased from 16% in 2010 to 4% in 2016, 
and variation between the five Danish regions was reduced 
from 7% to 24% in 2010 to 1% to 6% in 2016 (Fig. 1).
The Australian Orthopaedic Association National Joint 
Replacement Registry
Provision of information to orthopaedic surgeons is one of 
the most effective means of influencing outcomes of joint 
replacement surgery as they are best placed to influence 
change. The Australian Orthopaedic Association National 
Joint Replacement Registry (AOANJRR), established in 
1999, provides information in multiple ways, including the 
Annual Report, regular Scientific Presentations of register 
data and the provision of individual surgical outcomes. 
Surgeons use this information to improve the outcomes of 
THA; examples include the reduction in use after identifica-
tion of outlier prostheses such as the ASR,54,55 a reduction 
in the overall use of resurfacing hip replacement and its 
use largely in males aged < 65 years, and encouraging the 
use of cemented femoral stems in older patients.56
The AOANJRR has continually worked to improve the 
quality and timing of the information provided to sur-
geons. All Australian orthopaedic surgeons who have per-
formed joint replacement surgery can access their personal 
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information through a secure Web portal which was first 
made available in 2009. This information is up to date 
within four to six weeks of procedures being recorded in 
the register. Surgeons can download a complete report of 
the outcome of all joint replacements that they have per-
formed with a detailed analysis of the rates of revision of 
the prostheses they have used with tables of the types and 
reasons for the revisions. They also are given a funnel plot 
that displays the variation in revision rate by volume of 
procedures performed by the surgeon, with the national 
average and the 95% and 99.7% upper confidence limits 
displayed. The individual surgeon is represented by a 
green diamond that demonstrates their performance with 
respect to their peers (Fig. 2). Funnel plots are provided for 
several options associated with THA including overall out-
comes for all diagnoses and all types for revisions, and out-
comes for specific revision diagnoses such as prosthesis 
dislocation or revision for infection within two years. This 
enables surgeons to identify their performance, compare 
themselves to the national average and examine the rea-
sons for revision. The Australian Orthopaedic Association 
has recommended access of a surgeon’s individual reports 
with funnel plot data be counted as a specific requirement 
of ongoing Continuous Professional Development for 
those surgeons performing joint replacement.
Australian orthopaedic surgeons are making increasing 
use of register data; feedback from surgeons indicates that 
the process is an important element in the way they prac-
tice and will often motivate change, especially if they are 
outside the norms of national outcomes. Examples where 
surgeons use register data on a regular basis include tables 
of outcomes of specific prostheses and figures of revision 
rates by age or gender. Surgeons can interact with patients 
in consultations to provide them with accurate, up-to-
date and unbiased information and register data can be 
used to show each patient the typical outcomes for other 
patients with similar demographic and co-morbidity 
profiles.
The National Joint Registry for England, Wales, Northern 
Ireland and the Isle of Man
The National Joint Registry for England, Wales, Northern 
Ireland and the Isle of Man (NJR) was established in 2002 
with the intention of identifying implants with a higher 
than expected failure rate and in the event of a ‘recall’ to 
be able to notify patients so that appropriate action could 
be taken. Over the years, the NJR has evolved considerably 
and now provides specific data and feedback, and reports 
to a number of ‘stakeholders’ (Table 1).
Before the NJR, there was very little useful information 
on national activity and performance in relation to hip 
replacement surgery. The data and reports provide insight 
and reflection and the regulatory components drive 
accountability and patient safety. In relation to implant 
monitoring two levels of outlier have been defined:57
 • Level 1: An implant has a patient time incidence rate 



















Fig. 1. The percentage of primary THA patients diagnosed with osteoarthritis of the hip receiving blood transfusion within seven 
days from surgery during years from 2010 to 2016.5
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that have been used in at least 100 primary operations 
in the NJR.
 • Level 2: An implant has a PTIR of at least twice the 
overall PTIR, for implants that have been used in < 100 
primary operations in the NJR. Or when an implant has 
a PTIR of at least one and a half times the overall PTIR, 
for implants that have been used in at least 100 pri-
mary operations in the NJR.
As of January 2017, 2806 different combinations of hip 
stem/cup implants have been monitored with 17 Level 1 
outliers and 40 Level 2 outliers.
The NJR did not prevent the problems with MoM bear-
ings but it did identify the failure at an early stage and 
reported this to the Medicines and Healthcare Products 
Regulatory Agency. This resulted in regulatory action and 
a significant change in practice. It was recognized that 
enhanced post-market surveillance would be useful and 
an initiative called ‘Beyond Compliance’ was introduced 
in 2012.58 It was named Beyond Compliance because this 
was voluntary and beyond the European regulatory 
requirements.
The NJR supplies data to the Orthopaedic Device Evalu-
ation Panel (ODEP).59 The panel consists of clinicians and 
other members who invite the industry to provide data 
from a variety of sources (not just register data) on the 
implants. The ODEP then consider the submission and 
provide a benchmark at 3, 5, 7, 10 and 13 years. The 
strength of the submission is graded from A*, A, B and C 
depending on the quality of the data submitted at the 
appropriate benchmark period.
The NJR monitors potential component mismatches as 
the data are submitted. Examples of this would be incom-
patible head and liner combination.60 If these data are 
entered, the hospital is alerted to check for a potential 
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Fig. 2. Funnel plot of surgeon’s primary THA (excluding large head metal-on-metal) for all diagnoses with revision for any reason.
Table 1. The National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) supports performance and regulation.
Activity Objective How does it do this? Other bodies Reporting period
Clinician performance To provide feedback Clinician feedback portal Clinician and Hospital Biannual
Hospital performance To alert on adverse performance Annual clinical report and NHS 
Choices website
Hospital, CQC and NHS Improvement Biannual
Implant performance To identify implants with inferior 
performance
Implant performance committee MHRA Biannual
New Technology Safe introduction of new devices Providing data Beyond Compliance Daily
Benchmarking Safe use of implants Providing data ODEP Annual
Safety Component mismatch Web-based alerts NJR and Hospital Daily
Service Development Service improvement GIRFT programme GIRFT programme and NHS Improvement Annual
NHS, National Health Service; CQC, Care Quality Commission; MHRA, Medicines and Healthcare Products Regulatory Agency; OPED, Orthopaedic Device Evalua-
tion Panel; GIRFT, Getting it Right First Time.
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Future perspective
Data completeness and quality
There is a constant need for validation of data regarding 
completeness and quality. Completeness requires that all 
patients can be identified in more than one register in the 
region or country. Several registers do these evaluations 
routinely, but others are not able to do so.
Regarding data quality, there is a need for the use of 
implant barcodes and catalogue numbers to identify spe-
cific implants at risk including sizes, offset etc. Regarding 
revision surgery, there is a discrepancy in the definition 
between registers which is why harmonization is needed. 
Several registers have shown that only around 60% of 
revisions due to infections are captured in national regis-
ters, which is a clear limitation.61 By merging with other 
databases holding information on bacteria cultures, regis-
ters can capture around 90% of the infections. Thus, 
merging of databases is a way to go for better data quality 
on infections.
Research
The registers have been used in research for years.62 
Research using the national registers as a source of data 
will continuously play a major role in future improve-
ment of practice. The focus of register research should 
not only be on the implants, where differences may be 
small, but also on patient selection and complications. 
Patient selection is a major task and the registers only 
holds information on those who have had surgery. How-
ever, in some countries there are registers on patients 
with osteoarthritis treated non-operatively.63 Registers 
may also play a more important role in executing rand-
omized controlled trails (RCT) designed for a register 
(RRCT). Such a RRCT may be much more powerful than 
traditional RCTs with an increased efficiency and cost-
effectiveness.64 By adding a randomization feature in a 
register, unselected consecutive inclusion can be 
done. This may overcome the limitations of RCTs where 
generalizability and statistical power in particular can be 
problematic. Other possibilities are to perform cluster 
randomization at department level using register param-
eters as primary or secondary outcomes or merging with 
other databases.
Collaboration with health authorities
The registers provide data and produce reports but other 
bodies, typically health authorities, provide the clinical 
governance and regulation. In Europe, the rules are based 
on European Union (EU) Council Directives. Health 
authorities receive information about implant perfor-
mance and recalls from the industry. In many countries, 
there is no direct collaboration between the registers and 
health authorities, which may delay crucial information to 
reach the surgeons and have severe consequences for the 
patients. This is exemplified by the ASR recall from DePuy 
in 2010: the AOANJRR published concerns regarding this 
implant in the annual report 2006. The year after, the ASR 
was identified as an outlier. Thus, it took three years and 
many thousands of operations before the information 
came to the authorities and resulting in withdrawal of the 
implant from the market. This underlines that there is a 
need for better collaboration between registers and health 
authorities.
Collaboration between registers
There is a need for the sharing of results between regis-
ters. Some registers are too small to study rare events 
such as implant fracture or outcome for rare patient 
groups, which is why the merging of databases between 
countries can be attractive. The focus should be implant 
outliers and observation of new implants on the market. 
This was the motivation for the Nordic countries where 
hip, knee and shoulder arthroplasty registers have been 
merged.65
Post-market surveillance
Post-market surveillance is the long-term monitoring of 
safety and efficacy of the implants for the benefit of the 
patients. Europe has a common regulatory environment 
and the new EU device regulation will enforce post- 
market surveillance.66 Industry has to react to poor results 
together with the health authorities in order to have safe 
implants on the market and, further, industry has to 
deliver documentation for their products in order to keep 
them on the market necessitating collaboration with the 
registers. One important role for the registers is to collect 
patient characteristics and outcomes other than revision 
procedures (e.g. co-morbidity, use of medication, smok-
ing status and PROMs) in order to improve analyses on 
register data. This information might be achieved by link-
age to other data sources including national patient regis-
ters and prescription databases.67 Data have to be read 
and understood by industry which may require consul-
tancy with register experts.
Development of intelligent decision tools
With the rapidly growing literature, we cannot expect that 
every surgeon is updated on risk factors for revision and 
inferior outcome of THA. Moreover, it is not likely that cli-
nicians can put all these data together and extrapolate the 
results. The use of artificial intelligence by extraction from 
big databases followed by machine-learning through 
identifying risk factors will have a future within the treat-
ment of the patients.68 It is obvious that registers that hold 
the results of the average surgeon and hospital deliver 
data for such intelligent systems that can automatically be 
updated. Indeed, it is an attractive vision for the future 
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that these technologies can play a role in the decision-
making for treatment which may make the treatment 
safer, more efficient and cost-effective. However, there are 
significant challenges for the development and use of 
intelligent decision tools, including the need for evidence 
of effectiveness and safety, methodological issues (e.g. 
data quality and patient privacy and consent), and clinical 
implementation and utility.69
Conclusion
THA registers have influenced the orthopaedic practice in 
many aspects, e.g. changes in choice of implants and fixa-
tion method, peri-operative management and patient 
selection. Examples of impact from many THA quality reg-
isters have been demonstrated; however, more registers 
provide relevant information than those mentioned (e.g. 
the Dutch Arthroplasty Register and the New Zealand 
National Joint Register). Although open access survivor-
ship data are important for implant outlier detection, 
peer-reviewed scientific papers with adjustment and dis-
cussion are still vital to change treatment practices and 
several important papers have been published during 
recent years. Further, register data have been used in the 
concept of stepwise introduction of new implant technol-
ogy70,71 and in the future, THA registers may focus on 
extending the collaboration between registers to develop 
a stronger foundation for post-market surveillance and 
intelligent decision tools.
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